Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $36.0500 (-1.15%) ($35.7000 - $36.9800) on Wed. Jun. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.76% (three month average) | RSI | 42 | Latest Price | $36.0500(-1.15%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -2.4% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(48%) IWO(46%) IWC(43%) XBI(42%) IWM(41%) | Factors Impacting SAGE price | SAGE will decline at least -2.88% in a week (0% probabilities). VIXM(-27%) UUP(-13%) VXX(-9%) UNG(-1%) TBT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.88% (StdDev 5.76%) | Hourly BBV | 0 () | Intraday Trend | -0.9% | | | |
|
Resistance Level | $36.62 | 5 Day Moving Average | $36.37(-0.88%) | 10 Day Moving Average | $36.11(-0.17%) | 20 Day Moving Average | $36.62(-1.56%) | To recent high | -22.1% | To recent low | 38.9% | Market Cap | $1.872b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |